Beyond geographic novelty, this case provides valuable insights into the diagnostic challenges of distinguishing ALK-negative ALCL from more common gastrointestinal lymphomas in resource-limited settings and illustrates the application of novel therapeutic approaches with CD30-targeted therapy in this rare entity. This evidence concerns the gene ALK and anaplastic large cell lymphoma.